Janssen Research & Development to employ Total Brain data for new insights into depression
SAN FRANCISCO, Dec. 21, 2021 — Total Brain today announced that the company will license its International Study to Predict Optimized Treatment for Depression (iSPOT-D) research data to Janssen Research & Development, LLC. The company will use Total Brain’s iSPOT-D data to support clinical studies and precision drug development efforts to treat depression.
This perpetual license agreement is non-exclusive and makes Janssen R&D the third company to license the iSPOT-D data.
“Total Brain’s unique standardization and diverse complementary datasets are increasingly proving their value latency at the highest levels of clinical neuroscience,” explained Dr. Evian Gordon, Chairman and Chief Medical Officer, Total Brain.
iSPOT-D is the largest study of its kind in depression. The study identified objective indicators of treatment response in more than 1,700 depressed individuals using a range of clinical measures, including:
- Genetics (850,000 SNPs)
- A battery of cognitive tests
- Electroencephalogram (EEG)
- Event related potentials (ERP)
- Magnetic resonance imaging (MRI)
- Diffusion tensor imaging (DTI)
- Functional magnetic resonance imaging (FMRI)
- Mainstream clinical assessments.
This research study has been published in 55 peer reviewed publications.
About Total Brain
Total Brain is based in San Francisco and publicly listed in Sydney, AUS (ASX:TTB). Total Brain is a mental health and brain performance self-monitoring and self-care platform that has more than 1M registered users. Benefits for employers and payers include better mental healthcare access, lower costs and higher productivity. Benefits for providers include improved patient outcomes, tracking of evidence-based outcomes across the continuum of care, and a reduction in clinician fatigue. totalbrain.com
Media Contact:
Kelly Faville
Rocket Social Impact
978-621-6667
Kelly@Rocketsocialimpact.com